Supplemental Table 1. Retinal thickness and visual acuity outcomes.

	Week				
	0	3-4	12-16	24-28	48-52
Patient 1					
OD: BCVA OCT (μm)	83 237	87 253	79 249	85 241	73 287
OS: BCVA OCT (μm)	90 223	92 223	88 254	85 260	82 325
Patient 2					
OD: BCVA OCT (μm)	77 242	76 256	82 177	78 217	80 162
OS: BCVA OCT (μm)	60 Unable	63 Unable	68 213	78 195	77 193
Patient 3					
OD: BCVA OCT (μm)	65 Unable	65 Unable	79 Unable	-- --	84 205
OS: BCVA OCT (μm)	68 297	82 233	79 205	-- --	85 331
Patient 4					
OD: BCVA OCT (μm)	71 --	73 141	79 136	78 130	79 139
OS: BCVA OCT (μm)	59 --	49 180	50 Unable	35 169	87 169
Patient 5*					
OD: BCVA OCT (μm)	74 --	71 304	74 278	73 296	--
OS: BCVA OCT (μm)	35 --	57 --	71 285	74## 245	--

* Patient 5 elected to withdraw from the study at the 28-week follow-up visit due to travel constraints. At the time of study withdrawal, he was improving from a flare of his uveitis, deemed likely secondary to his missed daclizumab infusion at week 20.

Note: Patient underwent cataract surgery in the left eye for a visually significant posterior subcapsular cataract. This eye was excluded from statistical analysis of pre- and post-study visual acuities.

Patient was given sub-Tenon's triamcinolone acetate (40 mg) for uveitic flare OS at week 24. Visual acuity at that time was 55 ETDRS letters. VA subsequently improved to 74 letters at his week 28 visit.